Abstract
In the past few years, substantial progress has been made in technetium chemistry, including the synthesis of a variety of 99mTc-radiopharmaceuticals. This synthesis can be made feasible by using suitable reducing agents, highly specific ligands, appropriate buffer, and specific pH etc., which results in high radiochemical purity, minimum labeling time, commercial expediency of 99Mo/99mTc generator and high biological efficacy. 99mTc-radiopharmaceuticals have confirmed their worth in every span of life, especially in clinical and medical applications. Now 99mTc based pharmaceuticals are being used as diagnostic agents for a large number of infections caused by bacteria or any pathogens, tumors, cancers, ulcers etc. In this review, we discuss synthesis of a variety of 99mTc carrying biological molecules (antibiotics/antibodies/peptides/amino acids/macro and micro-organic molecules) along with their applications, to overview key innovations.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
In radiopharmaceuticals, the radioactive tracers are the main components to examining the function of body systems. Many radiopharmaceuticals are available for imaging purposes, which differ in terms of their physical characteristics, bio-distribution and radiation exposure. Medical images provide very helpful information to medical specialists for taking the important and right decision for diagnosis and therapeutic action. The overwhelming applications of radioisotopes in every span of life like agriculture, industry, chemistry, biology and nuclear medicine have made them critically significant. In some diseases radiopharmaceuticals can identify medical abnormalities at an early stage than other diagnostic tests. Synthesis of new radiolabeled agents (radiopharmaceuticals) is the major field of interest of nuclear medicine. Many radionuclides exist in nature, but naturally occurring isotopes do not have suitable half-life for medical use. Radiopharmaceuticals are being used in medical applications for molecular imaging and treatment of various infections, cancer and tumor [1–5]. As far as molecular imaging is concerned, it is a distinct technique capable to visualize, characterize and measure the biological processes at the molecular and cellular level, in humans and other living systems [6–13]. Nonetheless, the major radionuclide used for preparing diagnostic radiopharmaceuticals today is 99mTc, owing to its physical and chemical properties [14–16].
Salient features of 99mTc
Depending on clinical requirements, gamma or positron emissions, radiolabeling approaches, kinetics and coordinating systems, a variety of radioisotopes have been explored to develop radiopharmaceuticals. Among these, 99mTc based radiopharmaceuticals have confirmed their significance with ideal physical characteristics (t1/2 6 h, photon energy 140 keV, no corpuscular radiation), high radiochemical purity, minimum labeling time (10–30 min at room temperature sometimes), low cost, commercial expediency from 99Mo/99mTc generator and high biological efficacy (maximum assimilation by target organ and favorable pharmacokinetics). So more than 80 % of radiopharmaceuticals being used for diagnostic purposes contain 99mTc [5, 17]. Technetium (99mTc) has ideal energy of photons which is able to go inside the tissue and it can be detected easily. Due to the short half-life, it reduces the internal radiation hazard and has high limit of intake as compared to other radioisotopes commonly used in laboratories. The chemistry of 99mTc is very similar to Re because it is located in the periodic table near Rhenium element. Technetium is the 43 element in the periodic table and it is the member of transition metals group VIIB. The electron configuration of technetium is 4d5 5s2. Technetium has seven electrons in its outer most shell just like Krypton’s noble gas configuration and enthusiastically loses these electrons to yield the plus seven oxidation state of pertechnetate (\({\text{TcO}}_{4}^{ - }\)). It has distinguished coordination chemistry with a range of oxidation states between +1 and +7. It facilitates synthesis of technetium based radiopharmaceuticals with diverse ligand environments (O–, C–, Se, N–, P–, S– donor centers and their combinations) [18–31]. Sometimes this diversity does not assist reliable control of the oxidation state and stability of the complexes. On the other hand, it is a matter of fact that this diversity facilitates extensive opportunities for modifying technetium complexes, their structure and properties i.e. altering total charge of the complex, lipophilicity etc. [12, 13, 22–27]. Radiopharmaceuticals are frequently being synthesized with compounds of 99mTc in oxidation states +1, +3, +4, and +5, using 99Mo/99mTc generator, and suitable reducing agents like SnCl2·2H2O, SnF, HCl, NaBH4, Na2S2O4, Zn dust and FeSO4 etc. From a generator, 99mTc is eluted in the form of Na99mTcO4. Here negatively charged pertechnetate ion (\({}^{{99{\text{m}}}}{\text{TcO}}_{4}^{ - }\)) comprises 99mTc with +7 oxidation state. But in this form, 99mTc cannot make a stable complex with ligands, peptides or related molecules. Thus, it is necessary to lower the hepta valency of 99mTc [32–39]. This lowering of oxidation state is accomplished by using suitable reducing agent, specific ligand(s), and most probably the reaction conditions [40–45]. Previous studies revealed efficient labeling of \({}^{{99{\text{m}}}}{\text{TcO}}_{4}^{ - }\) and [99mTc (H2O)3 (CO3)]+ with a variety of bidentate and tridentate biologically active ligands having amine, N-heterocycles, aromatic and/or carboxylic donors [6–10, 21, 46]. Due to the ease of access and labeling, high specificity, rapid assimilation at infection or tumor site, i.e. early diagnosis, rapid blood clearance, high target to non-target ratio, less antigenicity, low toxicity, and high compatible half-life of 99mTc, it is a more desirable labeling radioisotope as compared to others for diagnostic purposes [32]. Also 99mTc complexes with antibiotics, drugs, peptides, nucleobases like purine and pyrimidine, amino acids etc. have proven their worth in many biochemical systems. These complexes either intercalate DNA or interfere with DNA replication machinery to intervene cancer, tumor, infection etc. The potential to incorporate this radionuclide (99mTc) into different targeting determinants has been the prime concern in developing specific diagnostic radiopharmaceuticals [5, 16]. Usually radiopharmaceuticals comprising ligands containing N- and S-centers prove to be the best for diagnosis of renal function [6], while that with O-centers are best for myocardial imaging [7]. Those with S- or P-centers are good for CNS receptor imaging, heart imaging and bone scintigraphy [8, 9, 47].
Factors affecting percentage labeling yield
In developing radiopharmaceuticals, maximum labeling yield and radiochemical purity are the main concern of a researcher. Several parameters including pH level, concentration of reducing agent (SnCl2) and coordination moiety i.e. ligand in the solution, and boiling time are optimized for good labeling yield and stable complex. Stability of a labeled moiety is of worth importance in terms of shelf-life and biodistribution. After labeling, in vitro stability, while in vivo stability after injecting in a living body, are of major concern [48–54]. As the radio isotopic atoms of the ligand moieties dissociate, the concentration of the labeled compounds in the shelf decreases. Sometimes such dissociation may continue or even increase in the in vivo domain. As it is much feasible for dissociated radioactive atoms to accumulate in different organs/tissues, the compounds with low labeling yields and/or substantial instability inside the body would not give desired biodistribution. Stability of radiolabeled compound is accomplished by temperature, pH and light etc. [10–13, 22]. An optimum pH with appropriate buffer solution plays significant role to acquire maximum radiochemical yield. Usually Phosphate buffer with pH 7 (6–8 in some cases) is found to be the best for a large number of systems [23–27, 55–59]. It is recommended that the injectable radiopharmaceutical should have pH compatible to blood pH (7.4) [12]. Also the selection of suitable reducing agent and its appropriate concentration is the basic requirement to get maximum radiochemical yield. Technetium in the form of pertechnetate ion (\({}^{{99{\text{m}}}}{\text{TcO}}_{4}^{ - }\)) with +7 oxidation state is actually nonreactive in nature and must be reduced to accelerate labeling reactions. Hydrated stannous chloride (SnCl2·2H2O) is found to be effective in synthesizing most of the radiopharmaceuticals. It is observed that an increase in concentration of SnCl2·2H2O facilitates increased formation of colloids that leads to decreased yield of the labeled complex [13]. As far as concentration of the starting material (ligands) is concerned, an increase in concentration results in maximum incorporation of 99mTc because of minimum limit to the volume used [22–25].
99mTc-labeled antibiotics
Pathogens (bacteria, viruses, parasites, fungi etc.) are regarded as the main source of variety of severe infectious diseases that may lead to mortality or morbidity. Primordial detection and recognition of the infection site allows prompt and successful treatment. Mostly delayed diagnosis of internal infections halts effective treatment and sometimes results in death as well. Actually the diagnosis of inflammatory processes relies on revealing anatomical/structural alterations of the affected organs and these changes are specific to the nature of the inflammation/infection under consideration. There is diversity in sensitivity, accuracy and specificity of various diagnostic techniques that mostly depends on the nature of the disease and pathophysiology operating there. The main objective of different imaging techniques is to incorporate the diagnostic functional data with that of anatomical/structural information in order to describe and characterize site, extent and activity of the disease [60].
After the development of various radiopharmaceuticals, the risk factors of morbidity or mortality accompanying infectious diseases have sharply decreased. 99mTc based radiopharmaceuticals have a significant role in distinguishing infections from inflammations. Although scintigraphy images are based on functional abrasions of tissues even then inflammatory or infectious progressions can be visualized in their early phases, when anatomical alterations are not yet obvious.
Ciprofloxacin, a frequently used antibiotic is found to be active against most of the gram positive and gram negative bacteria, was labeled with 99mTc. Ciprofloxacin is a fluoroquinolone-derivative antibiotic that binds to bacterial DNA gyrase and topoisomerase IV, and thus hinders the DNA replication [61]. The infections accurately detected by 99mTc labeled ciprofloxacin (infector) are septic arthritis, prosthetic device infections, osteomyelitis, endocarditis, deep seated abscesses and extrapulmonary tuberculosis [62]. While 99mTc-levofloxacin is found to be effective in diagnosing lungs, bone, sinus, airways, skin and joint infections, mostly caused by bacteria [63]. There are other fluoroquinolones derivatives also labeled which provide a higher labeling yield and better results than ciprofloxacin, viz. 99mTc-clinafloxacin [64], 99mTc-delafloxacin [65], 99mTc-fleroxacin [66], 99mTc-gemifloxacin [67], 99mTc-norfloxacin [68], 99mTc-rufloxacin [69] etc.
There are cephalosporins, antibiotics with greater effectiveness against gram-negative bacteria, 99mTc-cefepime [70], 99mTc-cefoperazone [26], 99mTc-ceftizoxime [71], 99mTc-ceftriaxone [72], 99mTc-cefuroxime [73], etc. There also certain 99mTc-antibiotics used to distinguish between sterile inflammation and bacterial infection namely 99mTc-cefepime [70], 99mTc-cefprozil [74], 99mTc-clarithromycin [75]. Whereas 99mTc-sulfadimidine can differentiate between septic and aseptic inflammation [76]. 99mTc-daunorubicin, Mitomycin C and 99mTc-doxorubicin are the only anticancer drugs which are also antibiotics, labeled with 99mTc for brain imaging [77], liver imaging [16], and tumor detection [78] respectively. There are also many others given in the Table 1.
99mTc-labeled proteins, peptides, amino acids, and their derivatives
Amino acids are the building blocks of peptides and proteins, which are the major structural and functional units of living systems. Amino acids are present in the body and used in the metabolism. When there are higher energy needs, amino acids are also used for energy fulfilment. Thus in tumors, where there are neoplastic cells with high energy needs, 99mTc-labeled amino acids or their derivatives prove to be good tumor locating agents. Some instances are 99mTc-l-carnitine [11], 99mTcN-PRODTC [79], 99mTcN-PHEDTC and 99mTcO-PHEDTC [80].
There are several receptors overexpressed in many types of tumors which can be bound by peptides. 99mTc-labeled peptides, thus, are used as to target these overexpressed receptors and potentially better tumor localization [81]. Angiogenesis in tumors depends on the integrin αvβ3 expression which is overexpressed in various metastasizing cancers [82]. Several 99mTc-labeled peptides have been synthesized which have high affinity to this receptor [83]. These include 99mTc-RGD and its derivatives 99mTc-[E-c(RGDfK)2]2 [83], 99mTc-3P-RGD2 [84], 99mTc-EDDA/HYNIC-RGD [85], given here within the Table 2. Other important receptors targeted for tumor imaging are somatostatin, GRP, EGF-R, and IGF-R, which are localized by 99mTc-octreotide [86], 99mTc-bombesin [87], 99mTc-Ior egf/r3 [50], 99mTc-ZIGF1R:4551-GGGC [88] respectively, and their derivatives.
Immunoglobulins or antibodies are proteins synthesized by the body in response to some antigenic stimuli, which specifically bind to those antigens. So in the cases of tumor or infection, antibodies could be used to target the surface antigen of a cancerous cell, or antigens of the inflammatory agent, respectively. Monoclonal antibodies (Mabs) are the candidate for radiolabeling because they provide enough binding specificity for localization of the target. Certain 99mTc-labeled Mabs are available for certain receptors or proteins, like 99mTc-Ior egf/r3 [50], 99mTc-D-AM-Fab and 99mTc-D-HF [89]. There are other proteins that specifically bind to other proteins like affibodies. Affibodies are non-antibody low molecular weight proteins. 99mTc-labeled affibody molecules serve as very good at localization of certain receptors overexpressed in tumors or other diseases, like 99mTc-ZIGF1R:4551-GGGC affibody which targets insulin growth factor type-1 receptors [88]. There are also many other protein and peptide derivatives labeled and given in the table 2.
Miscellaneous 99mTc-labeled organic molecules
Miscellaneous macro and micro-organic compounds have been labeled with 99mTc, as dictated by the nature and type of the ligand. Diphosphonates or bisphosphonates have affinities for bones. Many of their derivatives are labeled with 99mTc in search of a superior bone scintigraphy imaging agent, e.g. 99mTc-BIDP [90], 99mTc-BIPeDP [91], 99mTc-EIPrDP [47]. Nitroimidazoles have an affinity for hypoxic microenvironments of tumors, that’s why 99mTc-nitroimidazole [92], and its derivatives e.g. 99mTc-metronidazole [22], 99mTc-misonidazole [93], are used for tumor hypoxia imaging. There are other imidazoles like 99mTc-omeprazole [94], 99mTc-pantoprazole [95] and 99mTc-rabeprazole [96] used for stomach ulcer localization. Also there is 99mTc-tannic acid, one good radiotracer of stomach ulcer [49].
Our brain has billions of neurons which operate with nerve impulse. Nerve impulse is mediated as neurotransmitters bind to their receptors on the neuronal surface. Thus any ligand, might it be a neurotransmitter or its analog that can bind to these receptors, could be labeled for brain imaging. 99mTc-amine-thiophene-dione [97], 99mTc-gabapentin [98], 99mTc-Histamine [99], 99mTc-piracetam [100] are such examples. As the brain uses high energy for its functioning, glucose is a crucial requirement. Deoxyglucose derivatives are used for brain imaging like 99mTc-ECB-DG [28]. While hepatobiliary imaging is facilitated by organic acids like 99mTc-5-ALA [101], 99mTc-BPIDA [102], 99mTc-UDCA [103] etc. Cardiovascular diseases are detected and characterized by labeled β1-receptor and other myocardial receptor antagonists. Labeled β1-receptor antagonists are 99mTc-labetalol [104] and 99mTc-nebivolol. Another receptor angiotensin II is imaged by its 99mTc-antagonist i.e. 99mTc-losartan [105].
There are many 99mTc-labeled ligand preparations that help to detect and characterize many types of tumors. They usually detect tumors by receptor-specific binding. For example 99mTc(CO)3-(1-azido-1-deoxy-β-d-glucopyranoside) for tumor detection [106], 99mTc-clomiphene citrate is an estrogen receptor (ER) antagonist (breast and uterine cancers) [107], 99mTc(CO)3-folic acid derivative for folate receptors [108], 99mTc-DES-P [109], 99mTc-HYNIC-CHC for tubulin binding [110], 99mTc-methotrexate (MTX) for folate receptors [31], 99mTc-siRNA for chemokine receptor 4 expression [111] etc. Table 3 contains details of these and others. There are also non-antibiotic steroidal or non-steroidal compounds labeled with 99mTc for infection or inflammation imaging like 99mTc-2-aminoestrone-3-methyl ether [112], 99mTc-celecoxib [113], 99mTc-CSA-107 [114], 99mTc-diclofenac [56].
Conclusion and perspectives
99mTc labeled radiopharmaceuticals have an important place in medicine and health sciences. Because the role of 99mTc in the diagnostics is very well established owing to its physical and chemical properties (half-life of 6 h, gamma ray energy of 140 keV, easily obtained from a 99Mo/99mTc generator, low cost, minimal dose to the patient and negligible environmental impact). High labeling yield with minimal harsh conditions like low specific activity, neutral pH etc. make a radiopharmaceutical best for practical applications.
By looking at the data presented here in this article, we can conclude that there are some superior diagnostic agents than the others. Superior 99mTc-antibiotics include 99mTc-benzyl penicillin, 99mTc-cefepime, 99mTc-cefuroxime axetil, 99mTc-clarithromycin, 99mTc-delafloxacin, 99mTc-fleroxacin, 99mTcN- GTND, 99mTc-kanamycin, 99mTcN-MXND, 99mTc-pefloxacin, 99mTc-rifampicin, 99mTc-rufloxacin, 99mTc-sitafloxacin, 99mTcN-sitafloxacin dithiocarbamate (SFDE), 99mTc(CO)3-SFDE, and 99mTc-temafloxacin complex (TMC).
Superior labeled proteins and peptide radiotracers include 99mTc(CO)3-hexapep, 99mTc(CO)3-tetrapep 1, 99mTc(CO)3-tetrapept 2, 99mTc-(Nα-His)Ac-NT(8–13), 99mTc-3P-RGD2, 99mTc-anti-S. aureus antibody, 99mTc-bombesin derivative (HYNIC-BB 5-14), 99mTc-CpTT-octreotide, 99mTc-Cys-annexin V, 99mTc-EC-225, 99mTc-ECDG 99mTc-ghrelin peptide, 99mTc-HYNIC-annexin A5, 99mTc-HYNIC-GABA-Bombesin, 99mTc-HYNIC-Tyr3-octreotide (TOC), 99mTc-HYNIC-βAla-bombesin, 99mTc-insulin complex, 99mTc-Ior egf/r3, 99mTc-neurotensin analog, 99mTc-PADS, 99mTc-trifoban, 99mTc-trastuzumab, 99mTc-ubiquicidin 29-41, 99mTc-vasopressin and 99mTc-ZIGF1R:4551-GGGC.
Superior 99mTc-labeled organic molecules from Table 3 include a heterogeneous group of compounds. 99mTc-EIPrDP and 99mTc-IPeDP are superior bone scintigraphy agents. Superior liver imaging agents include 99mTc-5-ALA, 99mTc-CMC, 99mTc-Mitomycin C, 99mTc-Vincristine and 99mTc-UDCA. While a superior renal imaging agent is 99mTc-DMSA. Some, very suitable, brain imaging agents are 99mTc-amine-thiophene-dione, 99mTc-BAT-AV-45, 99mTc-histamine, 99mTc-piracetam and 99mTc-TRODAT-1. Some superior radiopharmaceuticals for gastrointestinal ulcer imaging are 99mTc-famotidine, 99mTc-omeprazole, 99mTc-pantoprazole, 99mTc-rabeprazole and 99mTc-tannic acid.
Superior tumor imaging agents are 99mTc-5FU, 99mTc-DES-P and 99mTc-methotrexate. While superior tumor hypoxia imaging agents are 99mTc(CO)3-4-nitroimidazole-triazole, 99mTc(CO)3-5-nitroimidazole-triazole, 99mTc-HYNIC-MN, 99mTc-misonidazole and 99mTc-PyDA. Some very efficient infection/inflammation imaging agents are 99mTc-2-aminoestrone-3-methyl ether, 99mTc-celecoxib, 99mTc-diclofenac, 99mTc-piroxicam, and 99mTc-fluconazole which is a fungal infection marker. Some superior and efficient heart imaging agents are 99mTc-labetalol, 99mTc-losartan, 99mTc-nebivolol and 99mTc-SestaMIBI.
References
Jurisson S, Berning D, Jia W, Ma D (1993) Coordination compounds in nuclear medicine. Chem Rev 93(3):1137–1156
Thakur M, Lentle BC (2006) Report of a summit on molecular imaging. Am J Roentgenol 186(2):297–299
Gambhir SS (2002) Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2(9):683–693
Weissleder R, Mahmood U (2001) Molecular imaging 1. Radiology 219:316
Unak P, Teksoz S, Biber Muftuler F, Medine E, Acar C, Yurekli Y (2007) 99mTc-glucoheptonate-guanine: synthesis, biodistribution and imaging in animals. J Radioanal Nucl Chem 275(2):379–385
Zobi F, Spingler B, Fox T, Alberto R (2003) Toward novel DNA binding metal complexes: structure and basic kinetic data of [M (9MeG)2 (CH3OH)(CO)3] + (M = 99Tc, Re). Inorg Chem 42(9):2818–2820
Zhang G, Fu N, Zhang H, Wang J, Hou X, Yang B, Shen J, Li Y, Jiang L (2003) Controlling pore size and wettability of a unique microheterogeneous copolymer film with porous structure. Langmuir 19(6):2434–2443
Francis AJ, Dodge CJ, Meinken G (2002) Biotransformation of pertechnetate by Clostridia. Radiochimica Acta 90(9–11/2002):791–797
Tait JF, Smith C, Gibson DF (2002) Development of annexin V mutants suitable for labeling with Tc(I)-carbonyl complex. Bioconjug Chem 13(5):1119–1123
Fazli A, Salouti M, Mazidi M (2013) 99mTc-ceftriaxone, as a targeting radiopharmaceutical for scintigraphic imaging of infectious foci due to Staphylococcus aureus in mouse model. J Radioanal Nucl Chem 298(2):1227–1233
Ibrahim I, Attallah K (2012) Synthesis of 99mTc-l-carnitine as a model for tumor imaging. Radiochemistry 54(4):407–411
Saha GB (2010) Fundamentals of nuclear pharmacy. Springer, Berlin
Yang Y-X, Lewis JD, Epstein S, Metz DC (2006) Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296(24):2947–2953
Hina S, Rajoka MI, Roohi S, Haque A, Qasim M (2014) Preparation, biodistribution, and scintigraphic evaluation of 99mTc-clindamycin: an infection imaging agent. Appl Biochem Biotechnol 174(4):1420–1433
Zhang J, Zhou X, Qin X (2012) Preparation, quality control and physico-chemical properties of 99mTc-BAT-AV-45. J Radioanal Nucl Chem 292(3):1377–1383
Bokhari TH, Akbar MU, Roohi S, Hina S, Sohaib M, Rizvi FA (2015) Synthesis, characterization and biological evaluation of 99mTc-labeled mitomycin C. J Radioanal Nucl Chem 303(3):1779–1784
Liu S, Edwards DS, Barrett JA (1997) 99mTc labeling of highly potent small peptides. Bioconjug Chem 8(5):621–636
Welch MJ, Redvanly CS (2003) Handbook of radiopharmaceuticals. Radiochemistry and applications, vol 3. Wiley, New York
Méndez-Rojas MA, Kharisov BI, Tsivadze AY (2006) Recent advances on technetium complexes: coordination chemistry and medical applications¶. J Coord Chem 59(1):1–63
Maruk AY, Bruskin A, Kodina G (2011) Novel 99mTc radiopharmaceuticals with bifunctional chelating agents. Radiochemistry 53(4):341–353
Banerjee T, Mitra S, Singh AK, Sharma RK, Maitra A (2002) Preparation, characterization and biodistribution of ultrafine chitosan nanoparticles. Int J Pharm 243(1):93–105
Ibrahim I (2009) Preparation of 99mTc-metronidazole as a model for tumor imaging. J Radioanal Nucl Chem 281(3):669–674
İlem-Özdemir D, Aşıkoğlu M, Özkılıç H (2013) Radiolabeling, quality control and kit formulation of a new 99mTc-labeled antibiotic: 99mTc-doxycycline hyclate. J Radioanal Nucl Chem 298(3):1635–1642
Von Guggenberg E, Dietrich H, Skvortsova I, Gabriel M, Virgolini I, Decristoforo C (2007) 99 mTc-labelled HYNIC-minigastrin with reduced kidney uptake for targeting of CCK-2 receptor-positive tumours. Eur J Nucl Med Mol Imaging 34(8):1209–1218
Yang DJ, Ozaki K, Oh C-S, Azhdarinia A, Yang T, Ito M, Greenwell A, Bryant J, Kohanim S, Wong VK (2005) 99mTc-EC-guanine: synthesis, biodistribution, and tumor imaging in animals. Pharm Res 22(9):1471–1479
Motaleb M (2007) Preparation of 99mTc-cefoperazone complex, a novel agent for detecting sites of infection. J Radioanal Nucl Chem 272(1):167–171
Sanad M (2013) Labeling and biological evaluation of 99mTc-azithromycin for infective inflammation diagnosis. Radiochemistry 55(5):539–544
Sadeghzadeh M, Charkhlooiea G, Daha FJ (2013) Synthesis, radiolabeling and biological evaluation of 99mTc-labeled deoxyglucose derivatives for molecular imaging. Iran J Pharm Res 12(3):273
Ünak P, Tunç M, Duman Y (1998) Labeling of penicillamine di sulfide with technetium-99m. Appl Radiat Isot 49(7):805–809
Dar UK, Khan IU, Javed M, Rasheed R, Mahmoud Z, Hyder SW, Bhatti SM, Anwar J (2011) Preperation of (99m) Tc labeled 5-fluorouracil as a potential diagnostic agent in advanced breast cancer: first clinical trial. Hell J Nucl Med 15(1):43–47
Dar UK, Khan IU, Javed M, Ahmad F, Ali M, Hyder SW (2011) Preparation and biodistribution in mice of a new radiopharmaceutical-technetium-99m labeled methotrexate, as a tumor diagnostic agent. Hell J Nucl Med 15(2):120–124
Signore A, Annovazzi A, Barone R, Bonanno E, D’Alessandria C, Chianelli M, Mather SJ, Bottoni U, Panetta C, Innocenzi D (2004) 99mTc-interleukin-2 scintigraphy as a potential tool for evaluating tumor-infiltrating lymphocytes in melanoma lesions: a validation study. J Nucl Med 45(10):1647–1652
Rennen HJ, Boerman OC, Oyen WJ, Corstens FH (2002) Scintigraphic imaging of inflammatory processes. Curr Med Chem Anti-Inflamm Anti-Allergy Agents 1(1):63–75
Lupetti A, Welling MM, Pauwels EK, Nibbering PH (2003) Radiolabelled antimicrobial peptides for infection detection. Lancet Infect Dis 3(4):223–229
Seabold JE, Forstrom LA, Schauwecker DS, Brown ML (1997) Procedure guideline for indium-111-leukocyte scinitgraphy for suspected infection/inflammation. J Nucl Med 38(6):997
Seabold JE, Palestro CJ, Brown ML, Datz FL (1997) Procedure guideline for gallium scintigraphy in inflammation. J Nucl Med 38(6):994
De Schrijver M, Streule K, Senekowitsch R, Fridrich R (1987) Scintigraphy of inflammation with nanometer-sized colloidal tracers. Nucl Med Commun 8(11):895–908
Akhtar MS, Qaisar A, Irfanullah J, Iqbal J, Khan B, Jehangir M, Nadeem MA, Khan MA, Afzal MS, Imran MB (2005) Antimicrobial peptide 99mTc-ubiquicidin 29–41 as human infection-imaging agent: clinical trial. J Nucl Med 46(4):567–573
Akhtar MS, Iqbal J, Khan MA, Irfanullah J, Jehangir M, Khan B, Muhammad G, Nadeem MA, Afzal MS, Imran MB (2004) 99mTc-labeled antimicrobial peptide ubiquicidin (29–41) accumulates less in Escherichia coli infection than in Staphlococcus aureus infection. J Nucl Med 45(5):849–856
McAfee JG, Gagne G, Subramanian G, Schneider RF (1991) The localization of indium-111-leukocytes, gallium-67-polyclonal IgG and other radioactive agents in acute focal inflammatory lesions. J Nucl Med 32(11):2126–2131
Rennen HJ, Boerman OC, Oyen WJ, Corstens FH (2001) Imaging infection/inflammation in the new millennium. Eur J Nucl Med 28(2):241–252
Boerman O, Laverman P, Oyen W, Corstens F, Storm G (2000) Radiolabeled liposomes for scintigraphic imaging. Prog Lipid Res 39(5):461–475
Martin-Comin J, Soroa V, Rabiller G, Galli R, Cuesta L, Roca M (2004) Diagnóstico de infección ósea con 99mTc-ceftizoxima. Revista Española de Medicina Nuclear 23(5):357
Gomes BV, Rabiller G, Iglesias F, Soroa V, Tubau F, Roca M, Martin-Comin J (2004) 99mTc-ceftizoxime scintigraphy in normal rats and abscess induced rats. Revista Espanola de Medicina Nuclear 24(5):312–318
Motaleb M (2007) Preparation and biodistribution of 99mTc-lomefloxacin and 99mTc-ofloxacin complexes. J Radioanal Nucl Chem 272(1):95–99
Tyagi S, Gencaslan S, Singh UP (2003) Nucleic acid base pair and mispair interactions with metal ions a thermodynamic aspect. J Chem Eng Data 48(4):925–932
Qiu L, Cheng W, Lin J, Chen L, Yao J, Pu W, Luo S (2013) Synthesis and evaluation of a series of 99mTc-labelled zoledronic acid derivatives as potential bone seeking agents. J Radioanal Nucl Chem 295(1):545–552
El-Tawoosy M (2013) Preparation and biological distribution of 99mTc-cefazolin complex, a novel agent for detecting sites of infection. J Radioanal Nucl Chem 298(2):1215–1220
Ibrahim IT, El-Tawoosy M, Talaat HM (2011) Labeling of tannic acid with technetium-99m for diagnosis of stomach ulcer. ISRN Pharm. doi:10.5402/2011/578570
Dias CR, Marczewski B, Moraes V, Barboza MFd, Osso Junior JA (2005) Tc-99m direct radiolabeling of monoclonal antibody ior egf/r3: quality control and image studies in mice. Braz Arch Biol Technol 48(SPE2):29–35
Unak P, Lambrecht F, Biber F, Medine İ, Teksoz S (2004) Labeling of famotidine with 99mTc and biodistribution studies on rats. J Radioanal Nucl Chem 261(3):587–591
Schechter NR, Yang DJ, Azhdarinia A, Kohanim S, Wendt R III, Oh C-S, Hu M, Yu D-F, Bryant J, Ang KK (2003) Assessment of epidermal growth factor receptor with 99mTc-ethylenedicysteine-C225 monoclonal antibody. Anticancer Drugs 14(1):49–56
Baishya R, Nayak DK, Chatterjee N, Halder KK, Karmakar S, Debnath MC (2014) Synthesis, characterization, and biological evaluation of 99mTc (CO) 3-labeled peptides for potential use as tumor targeted radiopharmaceuticals. Chem Biol Drug Des 83(1):58–70
Motaleb MA, Nassar MY (2014) Preparation, molecular modeling and biodistribution of 99mTc-phytochlorin complex. J Radioanal Nucl Chem 299(3):1759–1766
Abdel-Ghaney I, Sanad M (2013) Synthesis of 99m Tc-erythromycin complex as a model for infection sites imaging. Radiochemistry 55(4):418–422
El-Tawoosy M, Mahmoud A, Soliman S (2014) Preparation and preclinical evaluation of 99mTc-diclofenac as a model for inflammation imaging. Radiochemistry 56(6):622–627
Motaleb M (2010) Radiochemical and biological characteristics of 99mTc-difloxacin and 99mTc-pefloxacin for detecting sites of infection. J Labelled Compd Radiopharm 53(3):104–109
Bokhari TH, Akbar MU, Hina S, Usman M, Haq A, Roohi S, Saeed S, Iqbal M (2016) Direct labelling of medically interesting 99mTc-benzyl penicillin. Oxid Commun 1:187–194
Akbar MU, Bokhari TH, Roohi S, Zia KM, Zuber M, Parveen N, Ali N (2016) Development, optimization and biovalidation of 99mTc-insulin complex. Russ J Bioorg Chem 42(5):546–551
Raza Naqvi SA, Matzow T, Finucane C, Nagra SA, Ishfaq MM, Mather SJ, Sosabowski J (2010) Insertion of a lysosomal enzyme cleavage site into the sequence of a radiolabeled neuropeptide influences cell trafficking in vitro and in vivo. Cancer Biother Radiopharm 25(1):89–95
Fournier B, Zhao X, Lu T, Drlica K, Hooper DC (2000) Selective targeting of topoisomerase IV and DNA gyrase in Staphylococcus aureus: different patterns of quinolone-induced inhibition of DNA synthesis. Antimicrob Agents Chemother 44(8):2160–2165
Britton K, Wareham D, Das S, Solanki K, Amaral H, Bhatnagar A, Katamihardja A, Malamitsi J, Moustafa H, Soroa V (2002) Imaging bacterial infection with 99mTc-ciprofloxacin (infecton). J Clin Pathol 55(11):817–823
Naqvi SAR, Ishfaq MM, Khan ZA, Nagra SA, Bukhari IH, Hussain AI, Mahmood N, Shahzad SA, Haque A, Bokhari TH (2012) 99mTc labeled levofloxacin as an infection imaging agent: a novel method for labeling levofloxacin using cysteine ·HCl as co-ligand and in vivo study. Turk J Chem 36(2):267–277
Shah SQ, Khan MR (2011) Synthesis of techentium-99m labeled clinafloxacin (99mTc-CNN) complex and biological evaluation as a potential Staphylococcus aureus infection imaging agent. J Radioanal Nucl Chem 288(2):423–428
El-kawy O, Abdel-Razek A, Sayed M (2016) Radiolabeling, biological evaluation and molecular docking of delafloxacin: a novel methicillin-resistant Staphylococcus aureus infection radiotracer. J Radioanal Nucl Chem 308(3):1081–1088
Shah SQ, Khan MR (2011) Radiosynthesis and characterization of the 99mTc-fleroxacin complex: a novel Escherichia coli infection imaging agent. Transition Met Chem 36(3):283–287
Shah SQ, Khan MR (2011) Radiolabeling of gemifloxacin with technetium-99m and biological evaluation in artificially Streptococcus pneumoniae infected rats. J Radioanal Nucl Chem 288(1):307–312
Ibrahim I, Motaleb M, Attalah K (2010) Synthesis and biological distribution of 99mTc–norfloxacin complex, a novel agent for detecting sites of infection. J Radioanal Nucl Chem 285(3):431–436
Shah SQ, Khan MR (2011) Radiocharacterization of the 99mTc-rufloxacin complex and biological evaluation in Staphylococcus aureus infected rat model. J Radioanal Nucl Chem 288(2):373–378
Motaleb M, El-Kolaly M, Ibrahim A, El-Bary AA (2011) Study on the preparation and biological evaluation of 99mTc-gatifloxacin and 99mTc-cefepime complexes. J Radioanal Nucl Chem 289(1):57–65
Diniz SOF, Siqueira CF, Nelson DL, Martin-Comin J, Cardoso VN (2005) Technetium-99m ceftizoxime kit preparation. Braz Arch Biol Technol 48(SPE2):89–96
Sohaib M, Khurshid Z, Roohi S (2014) Labelling of ceftriaxone with 99mTc and its bio-evaluation as an infection imaging agent. J Labelled Compd Radiopharm 57(11):652–657
Lambrecht FY, Durkan K, Unak P (2008) Preparation, quality control and stability of 99mTc-cefuroxime axetil. J Radioanal Nucl Chem 275(1):161–164
Sanad MH, Borai E (2014) Performance characteristics of biodistribution of 99mTc-cefprozil for in vivo infection imaging. J Anal Sci Technol 5(1):1
Borai E, Sanad M, Fouzy A (2016) Optimized chromatographic separation and biological evaluation of 99mTc-clarithromycin for infective inflammation diagnosis. Radiochemistry 58(1):84–91
Amin A, Ibrahim I, Attallah K, Ali S (2014) 99m Tc-sulfadimidine as a potential radioligand for differentiation between septic and aseptic inflammations. Radiochemistry 56(1):72–75
Faheem A, Bokhari T, Roohi S, Mushtaq A, Sohaib M (2013) 99m Tc-daunorubicin a potential brain imaging and theranostic agent: synthesis, quality control, characterization, biodistribution and scintigraphy. Nucl Med Biol 40(1):148–152
Rizvi FA, Bokhari TH, Roohi S, Mushtaq A (2012) Direct labeling of doxorubicin with technetium-99m: its optimization, characterization and quality control. J Radioanal Nucl Chem 293(1):303–307
Liu M, Lin X, Song X, Cui Y, Li P, Wang X, Zhang J (2013) Synthesis and biodistribution of a novel 99mTc nitrido radiopharmaceutical with proline dithiocarbamate as a potential tumor imaging agent. J Radioanal Nucl Chem 298(3):1659–1663
Zhu J, Wang Y, Li Z, Zhang J (2014) Synthesis and biological evaluation of novel 99mTc-oxo and 99mTc-nitrido complexes with phenylalanine dithiocarbamate for tumor imaging. J Radioanal Nucl Chem 302(1):211–216
Laverman P, Sosabowski JK, Boerman OC, Oyen WJ (2012) Radiolabelled peptides for oncological diagnosis. Eur J Nucl Med Mol Imaging 39(1):78–92
Brooks PC, Clark R, Cheresh DA (1994) Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264(5158):569–571
Guleria M, Ghosh S, Das T, Sarma HD, Banerjee S. Preparation and bioevaluation of [99mTcN] 2+-labeled tetrameric complex of Ec (RGDfK) 2 as a radiotracer for imaging αvβ3 integrins in tumors. J Radioanal Nucl Chem:1–8
Yan B, Qiu F, Ren L, Dai H, Fang W, Zhu H, Wang F (2015) 99mTc-3P-RGD2 molecular imaging targeting integrin α v β 3 in head and neck squamous cancer xenograft. J Radioanal Nucl Chem 304(3):1171–1177
Decristoforo C, Faintuch-Linkowski B, Rey A, von Guggenberg E, Rupprich M, Hernandez-Gonzales I, Rodrigo T, Haubner R (2006) [99mTc] HYNIC-RGD for imaging integrin α v β 3 expression. Nucl Med Biol 33(8):945–952
Spradau TW, Edwards WB, Anderson CJ, Welch MJ, Katzenellenbogen JA (1999) Synthesis and biological evaluation of Tc-99m-cyclopentadienyltricarbonyltechnetium-labeled octreotide. Nucl Med Biol 26(1):1–7
Sadeghzadeh N, Ahmadzadeh M, Erfani M (2013) Evaluation of a new radiolabeled bombesin derivative with 99mTc as potential targeted tumor imaging agent. J Radioanal Nucl Chem 298(1):287–293
Mitran B, Altai M, Hofström C, Honarvar H, Sandström M, Orlova A, Tolmachev V, Gräslund T (2015) Evaluation of 99mTc-ZIGF1R: 4551-GGGC affibody molecule, a new probe for imaging of insulin-like growth factor type 1 receptor expression. Amino Acids 47(2):303–315
Khaw BA, Strauss HW, Carvalho A, Locke E, Gold HK, Haber E (1982) Technetium-99m labeling of antibodies to cardiac myosin fab and to human fibrinogen. J Nucl Med 23(11):1011–1019
Qiu L, Lin J, Cheng W, Wang Y, Luo S (2013) 99mTc-labeled butyl-substituted zoledronic acid as a novel potential SPECT imaging agent: preparation and preclinical pharmacology study. Med Chem Res 22(12):6154–6162
Qiu L, Cheng W, Lin J, Zhang S, Luo S (2013) Synthesis and pharmacological evaluation of 99mTc-labeled imidazolyl-containing diphosphonic acid as a novel bone imaging agent. J Labelled Compd Radiopharm 56(11):573–580
Bhadwal M, Mallia MB, Sarma HD, Banerjee S (2016) Neutral 99mTc (CO)3 complexes of “clicked” nitroimidazoles for the detection of tumor hypoxia. J Radioanal Nucl Chem 307(1):69–77
Mallia MB, Mathur A, Sarma HD, Banerjee S (2015) A 99mTc-labeled misonidazole analogue: step toward a 99mTc-alternative to [18F] fluromisonidazole for detecting tumor hypoxia. Cancer Biother Radiopharm 30(2):79–86
Sanad M (2013) Labeling of omeprazole with technetium-99m for diagnosis of stomach. Radiochemistry 55(6):605–609
Sanad M, Ibrahim I (2013) Radiodiagnosis of peptic ulcer with technetium-99m-pantoprazole. Radiochemistry 55(3):341–345
Sanad M, Ibrahim I (2015) Radiodiagnosis of peptic ulcer with technetium-99m labeled rabeprazole. Radiochemistry 57(4):425–430
Javed M, Khan IU, Mobeen S, Dar U-K, Hyder SW (2012) Synthesis, characterization and biodistribution of novel amine thiophene 99mTc labeled complex. Pak J Pharm Sci 25(2):381–387
Amin A, Abou Zid K, Bayoumi N, Abd El-hamid M (2009) Organic synthesis and biological evaluation of novel “3 + 1” mixed ligands of technetium-99m gabapentin as receptor imaging agents. J Radioanal Nucl Chem 283(1):55–62
Sanad M (2014) Novel radiochemical and biological characterization of 99mTc-histamine as a model for brain imaging. J Anal Sci Technol 5(1):1–7
Amin A, Sanad M, Abd-Elhaliem S (2013) Radiochemical and biological characterization of 99mTc-piracetam for brain imaging. Radiochemistry 55(6):624–628
Khan KU, Roohi S, Rafi M, Zahoor R, Iqbal Z, Ahmad M (2014) Evaluation of labelling conditions, quality control and biodistribution study of 99mTc-5-aminolevulinic acid (5-ALA): a potential liver imaging agent. J Radioanal Nucl Chem 300(1):225–228
Motaleb M, El-Said H, Atef M, Abd-Allah M (2012) Synthesis of 99mTc-biphenyl-2-ylcarbamoylmethyliminodiacetic acid for hepatobiliary imaging. Radiochemistry 54(3):274–278
Sanad M, El-Tawoosy M (2013) Labeling of ursodeoxycholic acid with technetium-99m for hepatobiliary imaging. J Radioanal Nucl Chem 298(2):1105–1109
Moustapha ME, Motaleb MA, Sanad MH (2016) Synthesis and biological evaluation of 99mTc-labetalol for β1-adrenoceptor-mediated cardiac imaging. J Radioanal Nucl Chem 309(2):511–516
Ibrahim I, Sanad M (2013) Radiolabeling and biological evaluation of losartan as a possible cardiac imaging agent. Radiochemistry 55(3):336–340
Khan IU, Shahid A, Dar UK, Ahmad F, Javed M (2016) Development and bioevaluation of (99m) Tc (CO)3-labeled (1-azido-1-deoxy-β-d-glucopyranoside) complex as a potential tumor-seeking agent. Pak J Pharm Sci 29(1):213–219
Ibrahim IT, Elkolally MT, Abd Elgany IY, Abd Albary A, Hodhod Elsayed M (2012) Preparation of 99mTc-clomiphene citrate as a novel agent for breast cancer imaging. ISRN Oncol 2012:7
Satpati D, Mukherjee A, Venkatesh M, Banerjee S (2011) Radiosynthesis and in vitro evaluation of 99mTc (CO)3-labeled folic acid derivative. J Radioanal Nucl Chem 290(1):89–93
Ünak P, Müftüler FZB, İçhedef Ç, Medine Eİ, Özmen K, Ünak T, Kilçar AY, Gümüşer FG, Parlak Y, Bilgin ES (2012) Synthesis, radiolabeling and in vivo biodistribution of diethylstilbestrol phosphate derivative (DES-P). J Radioanal Nucl Chem 293(1):57–66
Erfani M, Shamsaei M, Mohammadbaghery F, Shirmardi SP (2014) Synthesis and evaluation of a 99mTc-labeled tubulin-binding agent for tumor imaging. J Labelled Compd Radiopharm 57(6):419–424
Fu P, Tian L, Cao X, Li L, Xu P, Zhao C (2016) Imaging CXCR4 expression with 99mTc-radiolabeled small-interference RNA in experimental human breast cancer xenografts. Mol Imag Biol 18(3):353–359
Al Mutairi MS, Motaleb MA, Haress NG, Zaghary WA (2015) Biodistribution of 99mTc-2-aminoestrone-3-methyl ether as a potential radiotracer for inflammation imaging. J Radioanal Nucl Chem 303(1):237–244
Farouk N, El-Tawoosy M, Ayoub S, El-Bayoumy A (2011) Optimization of the reaction conditions for the preparation of 99mTc-celecoxib and its biological evaluation. J Radioanal Nucl Chem 290(3):685–690
Zahoor R, Roohi S, Ahmad M, Iqbal Z, Amir N, Tariq S, Savage PB (2013) Synthesis of 99mTc-cationic steroid antimicrobial-107 and in vitro evaluation. J Radioanal Nucl Chem 295(2):841–844
Ilem-Ozdemir D, Caglayan-Orumlu O, Asikoglu M, Ozkilic H, Yilmaz F, Hosgor-Limoncu M (2016) Evaluation of 99mTc-amoxicillin sodium as an infection imaging agent in bacterially infected and sterile inflamed rats. J Radioanal Nucl Chem 308(3):995–1004
Al-wabli R, Motaleb M, Kadi A, Al-rashood K, Zaghary W (2011) Labeling and biodistribution of 99mTc-7-bromo-1, 4-dihydro-4-oxo-quinolin-3-carboxylic acid complex. J Radioanal Nucl Chem 290(2):507–513
Mirshojaei S, Gandomkar M, Najafi R, Ebrahimi SS, Babaei M, Shafiei A, Talebi M (2011) Radio labeling, quality control and biodistribution of 99mTc-cefotaxime as an infection imaging agent. J Radioanal Nucl Chem 287(1):21–25
Mirshojaei S, Erfani M, Shafiei M (2013) Evaluation of 99mTc-ceftazidime as bacterial infection imaging agent. J Radioanal Nucl Chem 298(1):19–24
Mostafa M, Motaleb M, Sakr T (2010) Labeling of ceftriaxone for infective inflammation imaging using 99m Tc eluted from 99Mo/99m Tc generator based on zirconium molybdate. Appl Radiat Isot 68(10):1959–1963
Mirshojaei SF, Erfani M, Ebrahimi S, Esmaeil S, Talebi MH, Haj Hassan Abbasi F (2010) Freeze-dried cold kit for preparation of 99mTc-ciprofloxacin as an infection imaging agent. Iran J Nucl Med 18(2):45–51
Siaens RH, Rennen HJ, Boerman OC, Dierckx R, Slegers G (2004) Synthesis and comparison of 99mTc-enrofloxacin and 99mTc-ciprofloxacin. J Nucl Med 45(12):2088–2094
Shah SQ, Khan MR (2011) 99mTcN-gatifloxacin dithiocarbamate complex: a novel multi-drug-resistance Streptococcus pneumoniae (MRSP) infection radiotracer. J Radioanal Nucl Chem 289(3):903–908
Shah SQ, Khan AU, Khan MR (2011) Synthesis, biological evaluation and biodistribution of the 99mTc-garenoxacin complex in artificially infected rats. J Radioanal Nucl Chem 288(1):207–213
Shah SQ, Khan AU, Khan MR (2011) Radiosynthesis and biodistribution of 99mTcN-garenoxacin dithiocarbamate complex a potential infection imaging agent. J Radioanal Nucl Chem 288(1):59–64
Shah SQ, Khan AU, Khan MR (2011) 99mTc (CO) 3-garenoxacin dithiocarbamate synthesis and biological evolution in rats infected with multiresistant Staphylococcus aureus and penicillin-resistant Streptococci. J Radioanal Nucl Chem 288(1):171–176
Motaleb M, Alabdullah E, Zaghary W (2011) Synthesis, radiochemical and biological characteristics of 99mTc-8-hydroxy-7-substituted quinoline complex: a novel agent for infection imaging. J Radioanal Nucl Chem 287(1):61–67
Roohi S, Mushtaq A, Jehangir M, Malik S (2006) Synthesis, quality control and biodistribution of 99mTc-kanamycin. J Radioanal Nucl Chem 267(3):561–566
Shah SQ, Khan MR (2011) Evaluation of 99mTcN-moxifloxacin dithiocarbamate, as a potential radiopharmaceutical for scintigraphic localization of infectious foci. J Radioanal Nucl Chem 288(2):357–362
Shah SQ, Khan MR (2011) Radiosynthesis and biological evaluation of the 99mTc-tricarbonyl moxifloxacin dithiocarbamate complex as a potential Staphylococcus aureus infection radiotracer. Appl Radiat Isot 69(4):686–690
Shah SQ, Khan AU, Khan MR (2011) Radiosynthesis of 99mTc-nitrofurantoin a novel radiotracer for in vivo imaging of Escherichia coli infection. J Radioanal Nucl Chem 287(2):417–422
Shah SQ, Khan AU, Khan MR (2010) Radiosynthesis and biodistribution of 99m Tc-rifampicin: a novel radiotracer for in vivo infection imaging. Appl Radiat Isot 68(12):2255–2260
Motaleb M, Ayoub S (2013) Preparation, quality control, and biodistribution of 99mTc-rufloxacin complex as a model for detecting sites of infection. Radiochemistry 55(6):610–614
Moustapha M, Motaleb M, Shweeta H, Farouk M (2016) Synthesis and biological evaluation of technetium-sarafloxacin complex for infection imaging. J Radioanal Nucl Chem 307(1):699–705
Qaiser S, Khan A, Khan M (2010) Synthesis, biodistribution and evaluation of 99mTc-sitafloxacin kit: a novel infection imaging agent. J Radioanal Nucl Chem 284(1):189–193
Shah SQ, Khan AU, Khan MR (2011) Radiosynthesis and biological evaluation of 99mTcN-sitafloxacin dithiocarbamate as a potential radiotracer for Staphylococcus aureus infection. J Radioanal Nucl Chem 287(3):827–832
Shah SQ, Khan AU, Khan MR (2011) Radiosynthesis and biological evolution of 99mTc (CO)3-sitafloxacin dithiocarbamate complex: a promising Staphylococcus aureus infection radiotracer. J Radioanal Nucl Chem 288(1):131–136
Motaleb M (2009) Preparation, quality control and stability of 99mTc-sparafloxacin complex, a novel agent for detecting sites of infection. J Labelled Compd Radiopharm 52(10):415–418
Essouissi I, Darghoutha F, Saied N, Saidi M, Kanoun A, Saidi M (2015) Radiolabeling, quality control, and biodistribution of 99mTc-sulfadiazine as an infection imaging agent. Radiochemistry 57(3):307–311
Shah SQ, Khan MR (2012) Synthesis of 99mTc labeled temafloxacin complex and biodistribution in male wistar rats artificially infected with streptococci pneumonia. Adv Clin Exp Med 22(3):319–325
Shah SQ, Khan MR (2011) Radiosynthesis and biodistribution of 99mTc-tricarbonyl complex of temafloxacin dithiocarbamate: a potential Streptococci pneumoniae infection radiotracer. J Radioanal Nucl Chem 288(2):411–416
Shah SQ, Khan MR (2011) Radiocomplexation and biological characterization of the 99mTcN-trovafloxacin dithiocarbamate: a novel methicillin-resistant Staphylococcus aureus infection imaging agent. J Radioanal Nucl Chem 288(1):215–220
Shah SQ, Khan MR (2011) Synthesis of the 99mTc (CO) 3–trovafloxacin dithiocarbamate complex and biological characterization in artificially methicillin-resistant Staphylococcus aureus infected rats model. J Radioanal Nucl Chem 288(1):297–302
Gniazdowska E, Koźmiński P, Fuks L (2013) Synthesis, radiochemistry and stability of the conjugates of technetium-99m complexes with substance P. J Radioanal Nucl Chem 298(2):1171–1177
Gaonkar RH, Ganguly S, Baishya R, Dewanjee S, Sinha S, Gupta A, Ganguly S, Debnath MC (2016) Exploring the potential of 99mTc (CO) 3-labeled triazolyl peptides for tumor diagnosis. Cancer Biother Radiopharm 31(3):110–117
Zhang K, An R, Gao Z, Zhang Y, Aruva MR (2006) Radionuclide imaging of small-cell lung cancer (SCLC) using 99mTc-labeled neurotensin peptide 8–13. Nucl Med Biol 33(4):505–512
Kato M, Hazue M (1978) 99mTc (Sn) pyridoxylideneaminates: preparation and biologic evaluation. J Nucl Med 19(4):397–406
Huang K, Liu J, Zhu Z, Li X, Lu X (2007) Studies on the distribution and radioimmunoimaging of 99mTc-labeled 5-fluorouracil loaded immunological nanoparticles in tissues and human gastric carcinoma xenografts. Chin J Clin Oncol 4(5):307–312
Tsopelas C, Penglis S, Ruszkiewicz A, Bartholomeusz F (2003) 99mTc-alafosfalin: an antibiotic peptide infection imaging agent. Nucl Med Biol 30(2):169–175
Wong DW, Dhawan VK, Tanaka T, Mishkin FS, Reese IC, Thadepalli H (1982) Imaging endocarditis with Tc-99m-labeled antibody—an experimental study: concise communication. J Nucl Med 23(3):229–234
Ogawa K, Ohtsuki K, Shibata T, Aoki M, Nakayama M, Kitamura Y, Ono M, Ueda M, Doue T, Onoguchi M (2013) Development and evaluation of a novel 99mTc-labeled annexin A5 for early detection of response to chemotherapy. PLoS ONE 8(12):e81191
Aarntzen EH, Hermsen R, Drenth JP, Boerman OC, Oyen WJ (2016) 99mTc-CXCL8 SPECT to Monitor Disease Activity in Inflammatory Bowel Disease. J Nucl Med 57(3):398–403
Lu C, Jiang Q, Hu M, Tan C, Yu H, Hua Z (2015) Kit formulation for 99mTc-labeling of recombinant annexin V molecule with a C-terminally engineered cysteine. J Radioanal Nucl Chem 304(2):571–578
dos Santos EV, de Oliveira ML, do Nascimento JE (2015) Influence of humidity on radiochemical purity of 99mTc-ECD and 99mTc-Sestamibi. J Radioanal Nucl Chem 306(3):751–755
Yang DJ, Kim C-G, Schechter NR, Azhdarinia A, Yu D-F, Oh C-S, Bryant JL, Won J-J, Kim EE, Podoloff DA (2003) Imaging with 99mTc ECDG targeted at the multifunctional glucose transport system: feasibility study with rodents 1. Radiology 226(2):465–473
Taşdelen B (2011) The effect of selected preparation variables on the radiochemical purity of 99mTc-EDDA-HYNIC-TOC. J Radioanal Nucl Chem 287(2):491–495
Koźmiński P, Gniazdowska E (2015) Synthesis and in vitro/in vivo evaluation of novel mono-and trivalent technetium-99m labeled ghrelin peptide complexes as potential diagnostic radiopharmaceuticals. Nucl Med Biol 42(1):28–37
Staník R, Benkovský I (2011) 99mTc-labeling and molecular modeling of short dipeptide glycyl-l-proline. J Radioanal Nucl Chem 287(3):949–953
Orlova A, Malm M, Rosestedt M, Varasteh Z, Andersson K, Selvaraju RK, Altai M, Honarvar H, Strand J, Ståhl S (2014) Imaging of HER3-expressing xenografts in mice using a 99mTc (CO) 3-HEHEHE-ZHER3: 08699 affibody molecule. Eur J Nucl Med Mol Imaging 41(7):1450–1459
Blankenberg FG, Naumovski L, Tait JF, Post AM, Strauss HW (2001) Imaging cyclophosphamide-induced intramedullary apoptosis in rats using 99mTc-radiolabeled annexin V. J Nucl Med 42(2):309–316
Shirmardi S, Gandomkar M, Mazidi M, Shafiei M, Maragheh MG (2011) Synthesis and evaluation of a new bombesin analog labeled with 99mTc as a GRP receptor imaging agent. J Radioanal Nucl Chem 288(2):327–335
Behera A, De K, Chandra S, Chattopadhyay S, Misra M (2011) Synthesis, radiolabelling and biodistribution of HYNIC-Tyr3 octreotide: a somatostatin receptor positive tumour imaging agent. J Radioanal Nucl Chem 290(1):123–129
de Barros ALB, das Graças Mota L, de Aguiar Ferreira C, Corrêa NCR, de Góes AM, Oliveira MC, Cardoso VN (2013) 99mTc-labeled bombesin analog for breast cancer identification. J Radioanal Nucl Chem 295(3):2083–2090
Pervez S, Mushtaq A, Arif M (2001) Technetium-99m direct radiolabeling of lanreotide: a somatostatin analog. Appl Radiat Isot 55(5):647–651
Ekblad T, Tran T, Orlova A, Widström C, Feldwisch J, Abrahmsén L, Wennborg A, Karlström AE, Tolmachev V (2008) Development and preclinical characterisation of 99mTc-labelled Affibody molecules with reduced renal uptake. Eur J Nucl Med Mol Imaging 35(12):2245–2255
Ahrabi NZ, Erfani M, Parivar K, Beiki D, Jalilian AR (2014) Preparation and evaluation of a new neurotensin analog labeled with 99mTc for targeted imaging of neurotensin receptor positive tumors. J Radioanal Nucl Chem 299(1):461–469
Kennel SJ, Stuckey A, McWilliams-Koeppen HP, Richey T, Wall JS (2015) Tc-99m radiolabeled peptide p5+ 14 is an effective probe for SPECT imaging of systemic amyloidosis. Mol Imaging Biol:1–7
Darkovska-Serafimovska M, Janevik-Ivanovska E, Ugresic N, Djorgoski I (2015) Imaging of deep venous thrombosis using radioactive-labeled tirofiban. Bratisl Med J 2012 116(10):621–626
Rasaneh S, Dadras M (2016) The potential of SOCTA as a chelator for radiolabeling of trastuzumab with 99mTc. J Radioanal Nucl Chem 307(2):1353–1357
Zhao Y, Yao Q, Tan H, Wu B, Hu P, Wu P, Gu Y, Zhang C, Cheng D, Shi H (2014) Design and preliminary assessment of 99mTc-labeled ultrasmall superparamagnetic iron oxide-conjugated bevacizumab for single photon emission computed tomography/magnetic resonance imaging of hepatocellular carcinoma. J Radioanal Nucl Chem 299(3):1273–1280
Gniazdowska E, Koźmiński P, Bańkowski K, Ochman P (2014) 99mTc-labeled vasopressin peptide as a radiopharmaceutical for small-cell lung cancer (SCLC) diagnosis. J Med Chem 57(14):5986–5994
Wang J, Duan X, Mao H, Yang J, Tan C, Tian Y, Wu W (2013) Synthesis, 99mTc (CO)3-labeling and preliminary biodistribution studies of a novel colchicine complex. J Radioanal Nucl Chem 295(1):227–231
İçhedef Ç, Teksöz S, Şenocak K, Uçar E, Kılçar AY (2011) Preparation and bioevaluation of 99mTc-carbonyl complex of guanine. J Radioanal Nucl Chem 289(3):845–849
Ibrahim I, Wally M (2010) Synthesis, labeling and biodistribution of 99mTc-3-amino-2-quinoxalin-carbonitrile 1, 4-dioxide in tumor bearing mice. J Radioanal Nucl Chem 285(2):169–175
Ahmed N, Saeed AM, Fatima S, Zia N, Raza A, Zia M, Irfan J (2016) Synthesis, development and preclinical study of EDDA based 99mTc-5-fluorouracil for brain imaging. J Radioanal Nucl Chem 309(2):805–811
Gundogdu E, Ilem-Ozdemir D, Asikoglu M (2014) In vitro incorporation studies of 99mTc–alendronate sodium at different bone cell lines. J Radioanal Nucl Chem 299(3):1255–1260
Hawary DL, Motaleb MA, Farag H, Guirguis OW, Elsabee MZ (2011) Water-soluble derivatives of chitosan as a target delivery system of 99mTc to some organs in vivo for nuclear imaging and biodistribution. J Radioanal Nucl Chem 290(3):557–567
Motaleb M, El-Said H, Abdallah M, Atef M (2012) Synthesis and evaluation of 99mTc-NIDA and 99mTc-DMIDA complexes for hepatobiliary imaging. Radiochemistry 54(5):501–505
Yürekli Y, Ünak P, Ertay T, Müftüler FZB, Medine Eİ, Acar Ç (2010) Radiopharmaceutical model using 99mTc-DMSA to evaluate amifostine protection against cisplatin nephrotoxicity in rats. Turk J Nucl Med 19(3):105–109
Wang J, Zhang Y, Yang W, Xue J, Liu Y (2016) 99mTc-labeled colchicine for tumor imaging using DTPA as bifunctional chelating agent. J Radioanal Nucl Chem 307(2):1087–1092
Xia X, Feng H, Li C, Qin C, Song Y, Zhang Y, Lan X (2016) 99mTc-labeled estradiol as an estrogen receptor probe: preparation and preclinical evaluation. Nucl Med Biol 43(1):89–96
Wang Y, Song X, Zhang J (2015) Synthesis and evaluation of a 99mTc-labeled deoxyglucose derivative as a potential agent to target tumor. J Radioanal Nucl Chem 306(2):477–482
Amir N, Roohi S, Pervez S, Mushtaq A, Jehangir M, Miyashita Y, Okamoto K (2008) S-bridged complex of 99mTc with fac (S)-[Rh (aet) 3]: quality control, characterization and biodistribution studies in rats. J Radioanal Nucl Chem 279(1):25–30
Lupetti A, Welling MM, Mazzi U, Nibbering PH, Pauwels EK (2002) Technetium-99m labelled fluconazole and antimicrobial peptides for imaging of Candida albicans and Aspergillus fumigatus infections. Eur J Nucl Med Mol Imaging 29(5):674–679
Ibrahim A, Sakr T, Khoweysa O, Motaleb M, El-Bary AA, El-Kolaly M (2014) Formulation and preclinical evaluation of 99mTc-gemcitabine as a novel radiopharmaceutical for solid tumor imaging. J Radioanal Nucl Chem 302(1):179–186
Liu L, Zhong G, Wei Y, Zhang M, Wang X (2011) Synthesis and biological evaluation of a novel 99mTc complex of HYNIC-conjugated aminomethylenediphosphonate as a potential bone imaging agent. J Radioanal Nucl Chem 288(2):467–473
Liu L, Zhang M, Zhong G, Wang X (2011) Synthesis and biodistribution of a novel 99mTc complex of HYNIC-conjugated metronidazole as a potential tumor hypoxia imaging agent. J Radioanal Nucl Chem 287(3):847–852
Lin J, Qiu L, Cheng W, Luo S, Xue L, Zhang S (2012) Development of superior bone scintigraphic agent from a series of 99mTc-labeled zoledronic acid derivatives. Appl Radiat Isot 70(5):848–855
Gniazdowska E, Koźmiński P, Bańkowski K, Łuniewski W, Królicki L (2014) Synthesis, physicochemical and biological evaluation of technetium-99m labeled lapatinib as a novel potential tumor imaging agent of Her-2 positive breast cancer. Eur J Med Chem 87:493–499
Okarvi SM, Jammaz IA (2006) Preparation and in vitro and in vivo evaluation of technetium-99m-labeled folate and methotrexate conjugates as tumor imaging agents. Cancer Biother Radiopharm 21(1):49–60
Araújo RS, Fuscaldi LL, Takenaka IKTM, Vilela JMC, Andrade MS, Mosqueira VCF, Cardoso VN (2015) Characterization and in vivo evaluation of nanocapsules loading 99mTc-MIBI for intramammary study. J Radioanal Nucl Chem 303(3):2353–2360
Sakr T, Moustapha M, Motaleb M (2013) 99mTc-nebivolol as a novel heart imaging radiopharmaceutical for myocardial infarction assessment. J Radioanal Nucl Chem 295(2):1511–1516
Cachin F, Boisgard S, Vidal A, Filaire M, Auzeloux P, Culot D, Askienazy S, Madelmont J-C, Chezal J-M, Miot-Noirault E (2011) First ex vivo study demonstrating that 99mTc-NTP 15-5 radiotracer binds to human articular cartilage. Eur J Nucl Med Mol Imaging 38(11):2077–2082
Erfani M, Hassanzadeh L, Ebrahimi SES, Shafiei M (2013) 99mTc-labeling of a dithiocarbamate-DWAY fragment using [99mTcN] 2+ core for the preparation of potential 5HT1A receptor imaging agents. J Radioanal Nucl Chem 295(3):1783–1788
Li Z, Song X, Zhang J (2015) Synthesis and biological evaluation of novel 99mTc labeled ornidazole xanthate complexes as potential hypoxia imaging agents. J Radioanal Nucl Chem 306(2):535–542
Moustapha M, Motaleb M, Ibrahim I (2011) Synthesis of 99mTc-oxybutynin for M3-receptor-mediated imaging of urinary bladder. J Radioanal Nucl Chem 287(1):35–40
Surh Y, Spencer RP, Spitznagle LA, Hosain F, Lejczak B (1986) Technetium-99m-labeled phosphonic acid analog of serine: bone uptake. J Nucl Med 27(6):847–849
Banerjee I, Behera A, De K, Chattopadhyay S, Sachdev SS, Sarkar B, Ganguly S, Misra M (2015) Synthesis, characterization, biodistribution and scintigraphy of 99mTc-paclitaxel: a potential tracer of paclitaxel. J Radioanal Nucl Chem 304(2):633–643
El-Ghany E, Amine A, El-Sayed A, El-Kolaly M, Abdel-Gelil F (2005) Radiochemical and biological characteristics of 99mTc-piroxicam for scintigraphy of inflammatory lesions. J Radioanal Nucl Chem 266(1):125–130
Zhou X, Kong Y, Cao G, Zhang J (2013) Preliminary studies of 99mTc-PQQ-NMDAR binding and effect of specificity binding by mannitol. J Radioanal Nucl Chem 295(1):335–343
Sakr T, Essa B, El-Essawy F, El-Mohty A (2014) Synthesis and biodistribution of 99mTc-PyDA as a potential marker for tumor hypoxia imaging. Radiochemistry 56(1):76–80
Hung JC, Wilson ME, Brown ML, Gibbons RJ (1991) Rapid preparation and quality control method for technetium-99m-2-methoxy isobutyl isonitrile (technetium-99m-sestamibi). J Nucl Med 32(11):2162–2168
Motaleb M, Al-Musayeib N, Zaghary W, Shweeta H (2012) Synthesis and preclinical pharmacological evaluation of a novel 99mTc-shikonin as a potential tumor imaging agent. J Radioanal Nucl Chem 293(1):391–396
Xu YP, Luo SN, Pan DH, Wang LZ, Zhou YR, Yang M (2013) Synthesis and preliminary evaluation of 99mTc-spermine as a tumor imaging agent. J Radioanal Nucl Chem 295(3):1861–1866
Amin A (2013) Labeling of scorpion venom with 99mTc and its biodistribution. J Radioanal Nucl Chem 298(2):1421–1426
Al-Azzawi HM, Al-Nuzal SM, Abas SA, Ahmed S, Omran S, Risen R (2012) Labeling of new formulation of tin–sucralfate freeze-dried kit with technetium-99m and its biological evaluation. J Radioanal Nucl Chem 293(1):51–55
Ibrahim I, El-Tawoosy M, Talaat H (2013) Labeling of tannic acid with technetium-99m for diagnosis of stomach ulcer. Radiochemistry 55(4):423–427
Pervez S, Mushtaq A (2009) Formulation of a freeze-dried kit for the preparation of 99mTc-tetrofosmin. J Radioanal Nucl Chem 281(3):371–377
Muftuler FB, Unak P, Yolcular S, Kilcar AY, Ichedef C, Enginar H, Sakarya S (2010) Synthesis, radiolabeling and in vivo tissue distribution of an anti-oestrogen glucuronide compound, 99mTc-TOR-G. Anticancer Res 30(4):1243–1249
Kung M-P, Stevenson DA, Plössl K, Meegalla SK, Beckwith A, Essman WD, Mu M, Lucki I, Kung HF (1997) [99mTc] TRODAT-1: a novel technetium-99m complex as a dopamine transporter imaging agent. Eur J Nucl Med 24(4):372–380
Hina S, Roohi S, Rajoka MI, Haque A, Bokhari TH, Sohaib M (2015) Preparation, quality control and biological characterization of 99mTc-vincristine. J Radioanal Nucl Chem 304(2):553–561
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Akbar, M.U., Ahmad, M.R., Shaheen, A. et al. A review on evaluation of technetium-99m labeled radiopharmaceuticals. J Radioanal Nucl Chem 310, 477–493 (2016). https://doi.org/10.1007/s10967-016-5019-7
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10967-016-5019-7